IWILFIN is a breakthrough maintenance therapy that targets specific oncogenic pathways in high-risk neuroblastoma
IWILFIN works by blocking an enzyme called ornithine decarboxylase (ODC). ODC is the first and rate-limiting enzyme in the biosynthesis of polyamines, which are important to tumor proliferation.1
References:
1. IWILFIN. Prescribing information. USWM, LLC; 2024